Micro-ribonucleic acid-155 is a direct target of Meis1, but not a driver in acute myeloid leukemia

Haematologica. 2018 Feb;103(2):246-255. doi: 10.3324/haematol.2017.177485. Epub 2017 Dec 7.

Abstract

Micro-ribonucleic acid-155 (miR-155) is one of the first described oncogenic miRNAs. Although multiple direct targets of miR-155 have been identified, it is not clear how it contributes to the pathogenesis of acute myeloid leukemia. We found miR-155 to be a direct target of Meis1 in murine Hoxa9/Meis1 induced acute myeloid leukemia. The additional overexpression of miR-155 accelerated the formation of acute myeloid leukemia in Hoxa9 as well as in Hoxa9/Meis1 cells in vivo However, in the absence or following the removal of miR-155, leukemia onset and progression were unaffected. Although miR-155 accelerated growth and homing in addition to impairing differentiation, our data underscore the pathophysiological relevance of miR-155 as an accelerator rather than a driver of leukemogenesis. This further highlights the complexity of the oncogenic program of Meis1 to compensate for the loss of a potent oncogene such as miR-155. These findings are highly relevant to current and developing approaches for targeting miR-155 in acute myeloid leukemia.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Carcinogenesis / genetics
  • Gene Expression Regulation, Leukemic
  • Homeodomain Proteins / metabolism*
  • Humans
  • Leukemia, Myeloid, Acute / etiology*
  • Leukemia, Myeloid, Acute / genetics
  • Mice
  • MicroRNAs / antagonists & inhibitors*
  • MicroRNAs / metabolism
  • Myeloid Ecotropic Viral Integration Site 1 Protein / pharmacology*

Substances

  • Homeodomain Proteins
  • MicroRNAs
  • Mirn155 microRNA, mouse
  • Myeloid Ecotropic Viral Integration Site 1 Protein
  • homeobox protein HOXA9

Grants and funding